[go: up one dir, main page]

AU2931997A - Treatment of mood disorders with a growth hormone secretagogue - Google Patents

Treatment of mood disorders with a growth hormone secretagogue

Info

Publication number
AU2931997A
AU2931997A AU29319/97A AU2931997A AU2931997A AU 2931997 A AU2931997 A AU 2931997A AU 29319/97 A AU29319/97 A AU 29319/97A AU 2931997 A AU2931997 A AU 2931997A AU 2931997 A AU2931997 A AU 2931997A
Authority
AU
Australia
Prior art keywords
treatment
growth hormone
mood disorders
hormone secretagogue
secretagogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29319/97A
Inventor
Roy G. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614941.4A external-priority patent/GB9614941D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2931997A publication Critical patent/AU2931997A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU29319/97A 1996-05-07 1997-05-05 Treatment of mood disorders with a growth hormone secretagogue Abandoned AU2931997A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US1653896P 1996-05-07 1996-05-07
US60016538 1996-05-07
US1723796P 1996-05-10 1996-05-10
US60017237 1996-05-10
GB9614941 1996-07-16
GBGB9614941.4A GB9614941D0 (en) 1996-07-16 1996-07-16 Treatment of mood disorders with a growth hormone secretagogue
PCT/US1997/007508 WO1997041878A1 (en) 1996-05-07 1997-05-05 Treatment of mood disorders with a growth hormone secretagogue

Publications (1)

Publication Number Publication Date
AU2931997A true AU2931997A (en) 1997-11-26

Family

ID=27268393

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29319/97A Abandoned AU2931997A (en) 1996-05-07 1997-05-05 Treatment of mood disorders with a growth hormone secretagogue

Country Status (2)

Country Link
AU (1) AU2931997A (en)
WO (1) WO1997041878A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
EP1930021A3 (en) 1999-02-18 2008-06-18 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
EP1258250B1 (en) * 1999-12-28 2005-09-14 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
ES2333097T3 (en) 2000-05-31 2010-02-17 Raqualia Pharma Inc USE OF SECRETAGOGS OF GROWTH HORMONE TO STIMULATE GASTROINTESTINAL MOTILITY.
CA2426069A1 (en) * 2000-11-15 2002-05-23 David Michelson Treatment of anxiety disorders
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
ES2266798T3 (en) 2002-04-09 2007-03-01 Eli Lilly And Company SECRETAGODS OF GROWTH HORMONE.
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
EP2374455A3 (en) 2004-08-19 2012-03-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US7863449B2 (en) 2004-11-29 2011-01-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
AU2006330866A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP2009527569A (en) 2006-02-22 2009-07-30 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of muscarinic receptor
AU2007221214A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
EP2040706A2 (en) 2006-06-29 2009-04-01 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
JP2010500412A (en) 2006-08-15 2010-01-07 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of muscarinic receptor
WO2008021545A2 (en) 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EA200901077A1 (en) 2007-02-09 2010-04-30 Транзим Фарма, Инк. MACRO CYCLIC MODULATORS OF THE GREEL RECEPTOR AND THEIR APPLICATION
WO2009045519A1 (en) 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
TWI471146B (en) 2009-12-02 2015-02-01 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2014144330A1 (en) * 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of growth hormone or growth hormone receptor agonists to prevent or treat stress-sensitive psychiatric illness
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
CN108358863A (en) * 2018-03-08 2018-08-03 湖北佰智昂生物化工有限公司 A kind of method that zinc lewis acid Surfactant-Catalyzed prepares 5 '-substituted tetrazole compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5374721A (en) * 1992-10-14 1994-12-20 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5536716A (en) * 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5430144A (en) * 1993-07-26 1995-07-04 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone

Also Published As

Publication number Publication date
WO1997041878A1 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
AU2931997A (en) Treatment of mood disorders with a growth hormone secretagogue
AU1868595A (en) Human growth hormone
PL327634A1 (en) Growth hormone secretion stimulating compounds
AU5590098A (en) Endoprosthetic device with therapeutic compound
AU3220097A (en) Sleep quality improvement using a growth hormone secretagogue
PL338883A1 (en) Growth hormone secretion stimulating compounds
AU2334097A (en) 4-spiroindoline piperidines promote release of growth hormone
AU9471598A (en) Treatment of congestive heart failure with growth hormone secretagogues
AU3011497A (en) Novel human growth factors
AU2058697A (en) Treatment of sleep disorders
GB9622440D0 (en) Treatment of congestive heart failure with a growth hormone secretagogue
AU4131296A (en) Treatment of disorders with duloxetine
HUP9902095A3 (en) New process for the preparation of a growth hormone secretagogue
AU3207195A (en) Growth stimulating factors
AU1942995A (en) New use of growth hormone
AU4993497A (en) Convergent process for the preparation of a growth hormone secretagogue
AU7609298A (en) Treatment of heart failure with growth hormone
AU1926597A (en) Treatment of cocoa
GB9614941D0 (en) Treatment of mood disorders with a growth hormone secretagogue
AU7359496A (en) Methods for inhibiting cardiac fibroblast growth and cardiac fibrosis
AU5881996A (en) Methods of treatment using growth hormone antagonists
AU2766495A (en) Human criptin growth factor
AU4863397A (en) Use of growth hormone or a growth hormone secretagogue for promoting bone formation
AU2419097A (en) Use of growth hormone
AU1480197A (en) A purification process of a human growth hormone